UK Ibrance Patient Program (IPP) Study
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Interventions: DRUG: Palbociclib
Sponsor: Pfizer